Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 5, 2012, Pages 589-597

  Hoppe, Richard T ^a   Advani, Ranjana H ^a   Ai, Weiyun Z ^b   Ambinder, Richard F ^c   Aoun, Patricia ^d   Bello, Celeste M ^e   Bierman, Philip J ^d   Blum, Kristie A ^f   Chen, Robert ^g   Dabaja, Bouthaina ^h   Duron, Ysabel ⁱ   Forero, Andres ^j   Gordon, Leo I ^k   Hernandez Ilizaliturri, Francisco J ^l   Hochberg, Ephraim P ^m   Maloney, David G ⁿ   Mansur, David ^o   Mauch, Peter M ^p   Metzger, Monika ^q   Moore, Joseph O ^r   Morgan, David ^s   Moskowitz, Craig H ^t   Poppe, Matthew ^u   Pro, Barbara ^v   Winter, Jane N ^k   Yahalom, Joachim ^t   Sundar, Hema ^w   more..

^a STANFORD CANCER INSTITUTE   (United States)

^b UCSF Hellen Diller Family Comprehensive Cancer Center   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Latinas Contra Cancer   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ SEATTLE CANCER CARE ALLIANCE   (United States)

^o BARNES JEWISH HOSPITAL   (United States)

^p DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^q UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^r DUKE CANCER INSTITUTE   (United States)

^s VANDERBILT INGRAM CANCER CENTER   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u UNIVERSITY OF UTAH   (United States)

^v FOX CHASE CANCER CENTER   (United States)

^w National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; COMPUTER ASSISTED TOMOGRAPHY; EVENT FREE SURVIVAL; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84861813756     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0061     Document Type: Review

References (34)

1. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-1854.
2. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117:4208-4217.
3. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
4. Maeda LS, Advani RH. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 2009;21:397-400.
5. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-1168. (Pubitemid 41418320)
6. Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:1848-1853.
7. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 2011;22:910-915.
8. Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011;117:5314-5320.
9. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-1914.
10. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.
11. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-59. (Pubitemid 43053523)
12. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian- Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
13. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010;51:1337-1343.
14. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007;25:3902-3907. (Pubitemid 47477267)
15. Markova J, Kahraman D, Kobe C, et al. Role of [18F]-fluoro-2- deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma 2012;53:64-70.
16. Bonadonna G, Bonfante V, Viniani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835-2841. (Pubitemid 41079901)
17. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
18. Advani RH, Hoppe RT, Maeda LS, et al. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2011;81:1374-1379.
19. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642. (Pubitemid 46237440)
20. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399-408.
21. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289. (Pubitemid 36857790)
22. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-111.
23. Azim HA Jr, Pruneri G, Cocorocchio E, et al. Rituximab in lymphocyte-predominant Hodgkin disease. Oncology 2009;76:26-29.
24. Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010;21:2061-2068.
25. Fanale MA, Lai CM, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP [abstract]. Blood 2010;116:Abstract 2812.
26. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-4365.
27. Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [abstract]. Blood 2007;110:Abstract 644.
28. Advani RH, Horning SJ, Hoppe RT, et al. Frontline therapy of nodular lymphocyte predominant Hodgkin lymphoma with rituximab: the Stanford University experience [abstract]. Blood 2011;118:Abstract 2686.
29. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-1054. (Pubitemid 23114397)
30. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-2071. (Pubitemid 34680969)
31. Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009;146:158-163.
32. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-652. (Pubitemid 38297098)
33. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1312-1319. (Pubitemid 351911964)
34. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 8031.